X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

BIOG

Biotech Growth Trust extends strong performance in 2026

Year to date, the Trust’s NAV rose 36.2% and its share price gained 44.8%, ahead of the NASDAQ Biotechnology Index return of 24.3%...
Genflow Biosciences Plc

Genflow advances SIRT6 gene therapy

Genflow Biosciences has met the primary endpoint in its aged-dog SIRT6 gene therapy trial, adding biological evidence for its platform as the company progresses animal health partnership discussions...
PTRK

Physitrack wins three-year US healthcare contract

Physitrack has been selected as the digital rehabilitation platform for a US metropolitan safety net healthcare system, covering 86 practitioners. The three-year agreement has a potential total contract value of..
BIOG

Biotech Growth Trust stands out in a stronger biotechnology sector

Biotech Growth Trust has outpaced its biotechnology peers during a volatile market period, strengthening its position as one of the sector’s most closely watched investment trusts...
GNS

Genus reports strong FY26 profit growth, launches £60m share buyback

Genus reported a 35% rise in adjusted profit before tax for the year ended 30 June 2026, alongside stronger cash generation and reduced leverage. The company also announced a £60m..
GSK Shingrex

GSK’s Shingrix prefilled syringe approved in Japan

Japan’s health ministry has approved a ready-to-use prefilled syringe presentation of GSK’s Shingrix shingles vaccine, simplifying preparation and administration for healthcare professionals...
ONT

Oxford Nanopore to participate in September investor conferences

Oxford Nanopore will take part in the Morgan Stanley Global Healthcare Conference and RBC Capital Markets Pharma Services & Life Science Tools Virtual Conference in September, with fireside chats available..
Physitrack plc

Physitrack pushes AI deeper into physiotherapy workflows

Physitrack is integrating AI into everyday physiotherapy tasks while keeping clinical decisions under professional control...
GENF

Genflow Biosciences’ SLAB trial meets primary endpoint in aged dogs

Genflow Biosciences says its SLAB clinical trial has met its primary endpoint, with detailed results due to be presented in Toronto in October...

Physitrack selected by major US academic healthcare system for digital rehabilitation technology

Physitrack has been selected as the preferred digital rehabilitation technology provider by a large US academic healthcare system, with a proposed three-year contract worth up to approximately US$390,000. Go-live is..
AstraZeneca

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing..
BIOG

Biotech Growth Trust targets opportunity in global medical innovation

Biotech Growth Trust targets growth-stage biotechnology companies positioned around new treatments, industry consolidation and long-term healthcare demand...
Verici Dx Plc

Mayo Clinic moves transplant tolerance research towards larger clinical trials

Mayo Clinic is moving cell-based transplant tolerance research towards larger trials aimed at reducing lifelong dependence on anti-rejection drugs...
EDX Medical Group plc

EDX Medical reports diagnostic milestones and £330,000 revenue for FY2026

EDX Medical’s annual results highlight new cancer testing services, major diagnostic partnerships and £5.5 million in funding, alongside a £5.7 million full-year loss as the group continued investing in commercial..
PTRK

Physitrack Q2 2026 Shows ARR Growth, RTM Launch and Wellness Profit Recovery, Redeye

Physitrack's Q2 2026 delivered stronger ARR, Lifecare growth, a US RTM launch and renewed Wellness profitability...
Physitrack plc

Physitrack examines the business value of physical therapy certifications

Physical therapy certifications can improve career access and service positioning, but the financial return depends on how specialist skills are used and rewarded...
Genflow Biosciences Plc

Genflow Biosciences comes into focus as pet longevity demand grows

Genflow Biosciences moves into sharper focus as pet longevity shifts towards evidence, prevention and healthier ageing...
BIOG

Rhythm Pharmaceuticals gains Japan approval for IMCIVREE in hypothalamic obesity

Rhythm Pharmaceuticals has secured Japanese approval for IMCIVREE in acquired hypothalamic obesity, expanding the commercial opportunity for its lead rare-disease treatment...
EDX

EDX Medical begins second phase of Scottish Prostate Cancer Testing Initiative

EDX Medical has begun the second phase of the Scottish Prostate Cancer Initiative, with 12,500 more men set to receive free PSA testing as part of a programme aiming to..
AstraZeneca

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

BIOG

Biotech Growth Trust extends strong performance in 2026

Year to date, the Trust’s NAV rose 36.2% and its share price gained 44.8%, ahead of the NASDAQ Biotechnology Index return of 24.3%...
Genflow Biosciences Plc

Genflow advances SIRT6 gene therapy

Genflow Biosciences has met the primary endpoint in its aged-dog SIRT6 gene therapy trial, adding biological evidence for its platform as the company progresses animal health partnership discussions...
PTRK

Physitrack wins three-year US healthcare contract

Physitrack has been selected as the digital rehabilitation platform for a US metropolitan safety net healthcare system, covering 86 practitioners. The three-year agreement has a potential total contract value of approximately US$83,000, with go-live expected in Q4 2026...
BIOG

Biotech Growth Trust stands out in a stronger biotechnology sector

Biotech Growth Trust has outpaced its biotechnology peers during a volatile market period, strengthening its position as one of the sector’s most closely watched investment trusts...
GNS

Genus reports strong FY26 profit growth, launches £60m share buyback

Genus reported a 35% rise in adjusted profit before tax for the year ended 30 June 2026, alongside stronger cash generation and reduced leverage. The company also announced a £60m share buyback and said FY27 adjusted profit is expected to be in line with market expectations...
GSK Shingrex

GSK’s Shingrix prefilled syringe approved in Japan

Japan’s health ministry has approved a ready-to-use prefilled syringe presentation of GSK’s Shingrix shingles vaccine, simplifying preparation and administration for healthcare professionals...
ONT

Oxford Nanopore to participate in September investor conferences

Oxford Nanopore will take part in the Morgan Stanley Global Healthcare Conference and RBC Capital Markets Pharma Services & Life Science Tools Virtual Conference in September, with fireside chats available via webcast...
Physitrack plc

Physitrack pushes AI deeper into physiotherapy workflows

Physitrack is integrating AI into everyday physiotherapy tasks while keeping clinical decisions under professional control...
GENF

Genflow Biosciences’ SLAB trial meets primary endpoint in aged dogs

Genflow Biosciences says its SLAB clinical trial has met its primary endpoint, with detailed results due to be presented in Toronto in October...

Physitrack selected by major US academic healthcare system for digital rehabilitation technology

Physitrack has been selected as the preferred digital rehabilitation technology provider by a large US academic healthcare system, with a proposed three-year contract worth up to approximately US$390,000. Go-live is expected in late 2027, subject to completion of contracting...
AstraZeneca

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death...
BIOG

Biotech Growth Trust targets opportunity in global medical innovation

Biotech Growth Trust targets growth-stage biotechnology companies positioned around new treatments, industry consolidation and long-term healthcare demand...
Verici Dx Plc

Mayo Clinic moves transplant tolerance research towards larger clinical trials

Mayo Clinic is moving cell-based transplant tolerance research towards larger trials aimed at reducing lifelong dependence on anti-rejection drugs...
EDX Medical Group plc

EDX Medical reports diagnostic milestones and £330,000 revenue for FY2026

EDX Medical’s annual results highlight new cancer testing services, major diagnostic partnerships and £5.5 million in funding, alongside a £5.7 million full-year loss as the group continued investing in commercial growth and laboratory capabilities...
PTRK

Physitrack Q2 2026 Shows ARR Growth, RTM Launch and Wellness Profit Recovery, Redeye

Physitrack's Q2 2026 delivered stronger ARR, Lifecare growth, a US RTM launch and renewed Wellness profitability...
Physitrack plc

Physitrack examines the business value of physical therapy certifications

Physical therapy certifications can improve career access and service positioning, but the financial return depends on how specialist skills are used and rewarded...
Genflow Biosciences Plc

Genflow Biosciences comes into focus as pet longevity demand grows

Genflow Biosciences moves into sharper focus as pet longevity shifts towards evidence, prevention and healthier ageing...
BIOG

Rhythm Pharmaceuticals gains Japan approval for IMCIVREE in hypothalamic obesity

Rhythm Pharmaceuticals has secured Japanese approval for IMCIVREE in acquired hypothalamic obesity, expanding the commercial opportunity for its lead rare-disease treatment...
EDX

EDX Medical begins second phase of Scottish Prostate Cancer Testing Initiative

EDX Medical has begun the second phase of the Scottish Prostate Cancer Initiative, with 12,500 more men set to receive free PSA testing as part of a programme aiming to test 25,000 men across Scotland...
AstraZeneca

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple